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The identiﬁcation of improved diagnostic tests for tuberculosis has been identiﬁed as a global research priority.
Over the past decade, there has been renewed interest in the development and validation of novel diagnostic tools
for pulmonary tuberculosis that are applicable to resource-poor settings. These techniques are aimed primarily
at improving detection of the organism or a speciﬁc host immune response. Although most studies have focused
on determining the accuracy of novel tests in adults, it is likely they will also have the capacity to signiﬁcantly
improvethediagnosisofchildhoodtuberculosis.Improvingthequalityofclinicalsamplesobtainedfromchildren
with suspected tuberculosis remains an important research priority while awaiting validation of novel diagnostic
tests. This review will focus on a number of recent developments for the diagnosis of tuberculosis, with a speciﬁc
emphasis on the application of these new tests to children in settings where tuberculosis is endemic.
Because conﬁrming the diagnosis of pulmonary tuber-
culosis in young children is challenging, it is likely that
childhood tuberculosis remains underrecognized and
underreported. Nevertheless, it is estimated that chil-
dren make up 10%–15% of the total global tuberculosis
caseload [1]. Because tuberculosis in children may be
rapidly progressive [2] and may more frequently dis-
seminate or involve extrapulmonary sites, diagnostic
delay or uncertainty is likely to result in increased
morbidity and mortality.
In children, microbiologic conﬁrmation by culture
of the organism or demonstration of acid-fast bacilli
remainsthe gold standard,but in practice, this isseldom
achieved. First, it is difﬁcult to obtain representative
samples because young children are usually unable to
expectorate, and extrapulmonary sites may be less ac-
cessible for sample obtainment. Second, because cavi-
tary disease is unusual in younger children, results of
smear microscopy are often negative, and mycobacterial
culture is required.
In routine practice, in high-burden settings, clinicians
seldom wait for the results of culture to be available
before starting tuberculosis therapy in a child for whom
the diagnosis is suspected [3]. This is because of a re-
luctance to delay therapy in children who may have
rapidly progressive illness and also because the sensi-
tivity of culture for diagnosis of tuberculosis in children
is thought to be poor; thus, a negative culture result
cannot be used as a rule-out test.
In this context, there isan urgent need for improved
diagnostic algorithms and rapid and sensitive labo-
ratory tests for tuberculosis in children. This review
will focus on a number of advances in diagnosis of
pediatric pulmonary tuberculosis in recent years that
have resulted in incremental progress and will also
highlight recent advances in the diagnosis of adult
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children.
CLINICAL AND RADIOLOGICAL DIAGNOSIS OF
CHILDHOOD TUBERCULOSIS IS FREQUENTLY
UNRELIABLE
The clinical presentation of pulmonary tuberculosis in child-
hood is often nonspeciﬁc, and the history of illness may be acute
[2]. There is considerable subjectivity in the interpretation of
radiological ﬁndings, particularly hilar lymphadenopathy [4].
These challenges are particularly acute in children infected with
human immunodeﬁciency virus (HIV) [2] in the context of
which other opportunistic infections may present with over-
lapping clinical and radiological ﬁndings.
Because childhood tuberculosis typically occurs in resource-
poor settings, where access to highly trained health professionals
is restricted, scoring systems have been developed to improve
diagnostic accuracy. Such systems usually combine clinical and
radiological evidence of disease, with a history of tuberculosis
exposure or a positive tuberculin skin test (TST) result. There is
considerable literature describing the performance of such sys-
tems; however, many systems are poorly validated, may not be
generalizable to different epidemiological settings, and are not
adapted for use in HIV-infected children [5]. A recent evalua-
tion of 9 structured scoring systems clearly reveals the problem
[6].Theproportionof1445childrenwithsuspectedtuberculosis
who were assigned a tuberculosis diagnosis by the 9 different
systems varied from 6.9% to 89.2%. Agreement between these
systems was slight, with a median pairwise j statistic of 0.18.
Although such systems may be useful when designed for and
validated in particular epidemiological settings [2], caution
should be exercisedwhen generalizing thevalidity of a particular
system.
MICROBIOLOGIC CONFIRMATION OF DISEASE
IS CHALLENGING
Microbiologic conﬁrmation of tuberculosis in children by cul-
ture has not been part of routine care in high-burden settings
because of the unavailability of facilities, the difﬁculty in ob-
taining samples, the poor performance of smear microscopy,
and the perception that microbiologic yield is low. However,
several studies have now conﬁrmed that microbiologic conﬁr-
mation is feasible and useful to exclude drug-resistant tuber-
culosis [3]. In areas with high HIV and tuberculosis coinfection,
conﬁrmation is particularly valuable, because treatment of both
infections is associated with pill burden and complex drug in-
teractions.Forexample,druginteractionsmayoccurbetweenthe
rifamycins, especially rifampicin, and some of the nonnucleoside
reverse-transcriptase inhibitors or protease inhibitors [7].
In HIV-infected children, culture conﬁrmation may also be
important to distinguish nontuberculosis mycobacterial in-
fection and disseminated bacille Calmette–Gue ´rin from My-
cobacterium tuberculosis disease.
Methods Used to Enhance Specimen Recovery
Gastric Aspiration. For many years, 3 consecutive early
morning gastric lavage (GL) or aspirate (GA) samples have been
the standard of care. However, the culture yield from GL has
been disappointing; specimens must be taken on 3 sequential
days for optimal yield, and the procedure is unpleasant, rela-
tively invasive, and usually requires hospitalization. Thus, GL is
difﬁcult in ambulatory settings, where most children seek care.
Sputum Induction. Sputum induction has been successfully
used in a number of studies as an alternative to GL to obtain
a lower respiratory tract specimen for culture diagnosis. After
pretreatment with an inhaled bronchodilator, nebulization with
hypertonic (3%–5%) saline is performed, and secretions are
obtained by suctioning or by expectoration in older children [8].
A number of studies have now shown that collection of
induced sputum is feasible, safe, and effective even in infants.
In 2 large studies involving hospitalized infants in a tertiary
care facility in South Africa (median ages, 9 [9]a n d1 3[ 8]
months), samples were successfully obtained from 95% of
children. In the ﬁrst study, one induced sputum sample
yielded more positive culture results (10% of samples) than 3
did sequential GL samples (6% of samples), although in the
second study, the cumulative yield from 3 induced sputum
samples (87%) was greater than that of 3 GL samples (65%;
P 5 .018) [8, 9]). One induced sputum sample was equivalent
to3 GL samples [8]. The yield was similar in HIV-infected and
HIV-uninfected children.
Two studies evaluated the yield from sputum induction in
less ill children presenting for care at a peripheral level.
Among children with mild illness admitted to a case-veriﬁ-
cation ward as part of an infant tuberculosis vaccine trial, the
yields of single induced sputum and GL samples were equiv-
alent; however, positive culture results (from 2 GL to 2 in-
duced sputum samples) were obtained for only 10% of
admitted children [10]. More recently, a study performed in
a primary care clinic in South Africa, where 270 children
(median age, 38 months) with suspected tuberculosis had 2
induced sputum specimens obtained on sequential days, re-
ported microbiologic conﬁrmation in 11% of cases. Of im-
portance, microbiologic conﬁrmation improved the
diagnostic yield, identifying an additional 18 children who
would not have received treatment based on clinical judg-
ment, an increase in diagnostic yield of 22% [11].
Induced sputum samples have been successfully used for
conﬁrmation of childhood pulmonary tuberculosis in other
high-burden countries [12].
Precautions must be taken to prevent nosocomial trans-
mission during sputum induction. The procedure should be
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or in the open air,and sufﬁcienttimeshouldbe allowed between
procedures. Appropriate particulate respirators (N95 or FFP2)
should be used by staff.
SputuminductionhasanumberofadvantagesoverGL.Itcan
be performed as an outpatient procedure, it is relatively easy to
perform, and the yield is higher. Combined data from a number
of studies involving infants and young children that included
thousands of sputum induction procedures show that sputum
induction is safe, without any documented serious adverse
events [8–10, 13]. The remaining challenge is to change health
care workers’ perception that microbiologic diagnosis is not
possible in children and to achieve more widespread im-
plementation of sputum induction in children in health care
facilities.
Nasopharyngeal Aspiration. Nasopharyngeal aspiration
(NPA), achieved by passing a cannula through a nostril into the
nasopharynx, is an attractive diagnostic procedure because it is
minimally invasive and easy to perform. Early studies involving
persons with suspected tuberculosis from Peru [14] and Uganda
[15] suggested that the culture yield from NPA was similar to
that from GA (30% vs 38%; median age, 5 years [14]) or from
sputum induction (24% vs 22%; median age, 48 months [15]).
In contrast, in Yemen (n 5 213; median age, 5 years) [16], solid
mycobacterial culture results were positive for 7% of NPA
samples, 9% of GA samples, 8% of expectorated sputum sam-
ples, and 14% of induced sputum samples. Similarly, in 2 Pe-
ruvian studies involving 165 [17]a n d2 1 8[ 18] children, the
yield from NPA samples was lower than that from GA samples
(3.8% vs 6.8% and 10% vs 5.5%, respectively).
Alternative Methods to Augment Specimen Recovery. Al-
ternative methods include bronchoalveolar lavage (BAL), ob-
tainment of stomach contents with use of a string test [19], ear
swabs, and ﬁne needle aspiration of an enlarged lymph node
[20].BALisaresource-intensiveandinvasiveprocedurethathas
a lower yield for mycobacterial culture, compared with GL;
therefore, BAL is not indicated for microbiologic conﬁrmation
of tuberculosis [21]. The string test is not suitable for young
children (,4 years of age) and has not been well studied in
a pediatric population, although it has been shown to be well
tolerated by older children (median age, 8 years) [19]. An ear
swab provides a useful sample that can be easily obtained but is
limited to situations in which there is a discharging ear. Fine
needle aspiration and culture is a very useful adjunct to culture
of respiratory specimens when an enlarged lymph node is
present and when staff have been appropriately trained in the
procedure [20].
Noninvasive Specimens
Because young children swallow sputum, stool may contain
viable M. tuberculosis; however, stool has proved to be a poor
specimen for culture in 2 Peruvian studies, with culture yields
from stool samples and GA samples, of 1.4% and 6.8% [17]
and 1.8% and 10% [18], respectively, possibly because of the
difﬁculty in adequately decontaminating the sample without
destroying mycobacteria.
Urine samples are simple to collect and, although unlikely to
be culture positive except in cases of urinary tract tuberculosis,
may be useful for molecular diagnostics or antigen detection.
Rapid Liquid Culture Methods
Automated liquid culture systems, such as the mycobacterial
growth indicator tube (MGIT) (Becton Dickinson) offer sig-
niﬁcantly more rapid diagnosis than does conventional solid
culture (13.2 vs 25.8 days in a meta-analysis) [22]; however,
availability is limited because of cost and resource requirements.
The microscopic observation drug susceptibility (MODS)
technique, which involves visual inspection of growth in a liquid
culture system, has been proposed as a low-cost alternative.
MODS is substantially more sensitive than solid culture for
pediatric samples [18] and offers the advantage of simultaneous
detection of drug resistance. Implementation is somewhat com-
plex at present because of the need for reagents from multiple
suppliers, and the method requires highly trained operators.
Simple, rapid, and accurate identiﬁcation of M. tuberculosis
complex in cultured samples is now possible with use of an
inexpensive immunochromatographic assay (Capilia TB) [23].
ALTERNATIVES TO CULTURE FOR DETECTION
OF M. tuberculosis
Until very recently, the performance of nucleic acid ampliﬁca-
tion assays (NAAs) for the detection of M. tuberculosis DNA
or RNA in patient samples has been disappointing. In adults,
commercial assays display high speciﬁcity (pooled speciﬁcity,
97% [24]) but poor sensitivity for smear-negative samples
(pooled estimate, 66% [25]). Although there have been no large
studiesevaluatingtheperformanceofthesecommercialassaysin
children, in one study, the sensitivity of the Roche Amplicor
MTB test was disappointing (44%) [26]. The performance of in-
house assays has been highly variable [27], probably because of
variability in patient populations, DNA extraction and ampli-
ﬁcation protocols,andoperatorexperience.Asaresult,in-house
assays have not gained widespread acceptance.
Because NAA results can potentially be delivered in hours
or days rather than weeks, a positive NAA result from a highly
speciﬁc assay (such as the commercially available tests) may be
useful to rapidly conﬁrm a diagnosis, even if only for a subset of
patients. However, the widespread adoption of NAA has been
restricted by the need for specialized molecular laboratories and
experienced staff, which are seldom available in high-burden
settings.
Polymerase chain reaction (PCR)–based line probe assays,
such as the Genotype MTBDRplus (Hain Lifescience), are now
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Such tests offer sensitive and speciﬁc detection of isoniazid and
rifampicin resistance directly from smear-positive samples or
from positive culture samples. These assays have not speciﬁcally
been assessed in pediatric populations; however, because the
majority of pediatric samples are smear negative, their role
would be primarily for detection of resistance in positive culture
samples. Such assays require dedicated molecular facilities and
highly trained operators.
The development of real-time PCR detection of M. tuber-
culosis represents an important advance. Real-time PCR
allows simultaneous ampliﬁcation and detection of PCR
product, without the need for manipulation of PCR products
and the associated risk of amplicon contamination. Further-
more, real-time PCR permits the detection of several
different PCR products in the same reaction, allowing
simultaneous detection of tuberculosis and drug resistance
mutations.
However, the need for manual sample processing and DNA
extraction, both highly operator-dependent steps, remains an
obstacle to widespread implementation. There has therefore
been considerable interest in the recently published large eval-
uation study of the GeneXpert MTB/RIF assay in adult patients
[29]. This technology uses a cartridge-based automated DNA
extraction / real-time PCR ampliﬁcation and detection system
that is virtually operator independent. The test is able to si-
multaneously detect the presence of M. tuberculosis DNA and
rifampicinresistance.Theperformanceofthetestforadultswith
suspected tuberculosis was excellent, with a single test having
a sensitivity of 98.2% for smear-positive and 72.5% for smear-
negative tuberculosis. The speciﬁcity of the test among patients
without tuberculosis was 99.2%. This technology represents
a major advance in delivering highly sensitive NAA technology
in a format that is suitable for use at the microscopy center level
in developing countries. Results from the ﬁrst evaluation studies
of this technology in pediatric patient populations are expected
soon.
Because small fragments of M. tuberculosis DNA from dis-
integrating bacilli in the lungs and elsewhere may be ﬁltered
through the glomeruli, the detection of transrenal DNA in urine
has been studied. Results from adult studies are, however, ex-
tremely variable (sensitivity range, 7%–79% [30]), probably
related to differences in patient populations and sample collec-
tion and DNA extraction and ampliﬁcation protocols. The de-
tection of transrenal DNA has not yet been evaluated in
a pediatric population.
The detection of mycobacterial antigens, such as lip-
oarabinomannan (LAM)is an alternative to nucleic acid detection
in urine. LAM detection may be achieved in an enzyme-linked
immunosorbent assay (ELISA) format or in a lateral ﬂow test,
potentially useful at the point-of-care. The sensitivity of a LAM
ELISAin adultstudies has variedwidely [31];however, thetest is
most sensitive among patients with tuberculosis and advanced
HIV infection. There is a need to evaluate the performance of
this test in children with suspected disseminated tuberculosis
and those with HIV coinfection.
INTERFERON–g RELEASE ASSAYS AND
TUBERCULOSIS DISEASE
Interferon (IFN)–c assays (IGRAs) (QuantiFERON-TB Gold
assay [QFT-G], QuantiFERON-TB Gold In-Tube assay [QFT-
GIT; Cellestis], and T-SPOT.TB assay [Oxford Immunotec]) are
increasinglybeingusedasreplacementtestsforthe TSTinadults
[32]. However, data supporting their use speciﬁcally in children
are less clear and several questions concerning the use of IGRAs
in children remain unresolved [33].
Although a positive IGRA or TST result may indicate recent
M. tuberculosis exposure to support a diagnosis of tuberculosis
disease in a child with suspected tuberculosis, the true sensitivity
of IGRAs and TST for the diagnosis of pulmonary tuberculosis
can be determined only in children with culture-conﬁrmed tu-
berculosis disease. Of all the children for whom results of an
IGRA are available from published studies, 2% had culture-
conﬁrmed tuberculosis disease. Results from studies that in-
cluded $10 children with culture-conﬁrmed tuberculosis dis-
ease suggest a comparable sensitivity of 70%–90% for IGRAs
and TST among children in high-income countries (Table 1).
Studies that have compared the results of both assays
(T.SPOT.TB and QFT-G or QFT-GIT) in children with culture-
conﬁrmed tuberculosis disease in these settings appear to in-
dicate a comparable sensitivity between them. By contrast, in
low-income settings, IGRAs appear to be potentially less sensi-
tive for the detection of tuberculosis disease in children. The
underlying explanation for this discrepancy remains unknown.
In HIV-infected children, the sensitivity of an IFN-c enzyme-
linked immunospot assay (ELISPOT) was signiﬁcantly higher
than TST in young malnourished HIV-infected children in two
studies in South Africa [34, 35]. However, a similar sensitivity
was reported for QFT-G and TSTin 36 HIV-infected children in
a study from Romania [36].
Because the gold standard of culture conﬁrmation in children
often remains elusive, a diagnosis of highly probable tubercu-
losis disease is often made on the basis of compatible clinical
symptoms and signs, a tuberculosis contact history, and chest
radiograph ﬁndings consistent with tuberculosis [37]. In many
studies, the sensitivity of IGRAs in children with culture-
conﬁrmed and highly probable tuberculosis disease is reported
to reﬂect routine pediatric clinical practice. The sensitivity
of IGRAs, compared with TST, in studies that have included
$10 children with culture-conﬁrmed or probable tuberculosis
disease is shown in Table 2.
A combination of both TST and IGRA has been found to
increase sensitivity in several settings, suggesting that this
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with increased certainty [38–40]. When both tests are used,
consideration should be given to the timing of each test with
respect to the other. Because the TST reagent includes peptides
that are incorporated into IGRA, the potential of a prior TST to
boost a subsequent IGRA response remains a concern. Data that
have investigated the potential of a prior TST to boost a sub-
sequent IGRA response have reported inconsistent results, de-
pending on the timing of the second IGRA [41, 42].
Reﬂecting the current target market for IGRAs, the majority
of studies involving children have focused on the use of IGRA
for the diagnosis of latent tuberculosis (LTBI). Because of the
absence of a recognized gold standard, the sensitivity of IGRAs
for the detection of LTBI in children is more difﬁcult. Without
a gold standard, analysis of the results of IGRAs and TST with
respect to a tuberculosis contact history or gradient of exposure
is one way to potentially determine the superiority of one test
over another for the detection of LTBI. Although results are con-
ﬂicting, results of IGRAs appear to correlate better with deﬁned
M. tuberculosis exposure, compared with TST, in most [39, 43]
but not all studies [44, 45]. However, in view of the uncertainty
and lack of a deﬁnitive explanation underlying discordant results
between TSTand IGRA (mostly TST positive and IGRA negative),
coupled with the increased vulnerability of young children to
progress to tuberculosis disease after M. tuberculosis exposure,
many pediatricians may feel uncomfortable withholding pre-
ventive treatment in children with TST-positive and/or IGRA-
negative results [33, 46, 47]. The predictive value of a positive
TST for the development of tuberculosis disease has been well
described in children [48], whereas data on the positive and
negative predictive value of IGRAs in children remain scarce [49].
Several recent studies involving children have questioned
the performance of the QFT-G and QFT-GIT in young children
,5 years of age [50, 51]. In these studies, a great number of
indeterminate assay results have been reported, primarily as
a result of failure of the positive control response in the assay.
Reduced IFN-c production in response to mitogen stimulation
in young children has been described [52], and several studies
have shown an age-related change in the magnitude of T helper
cell cytokine secretion [53, 54].
The true role of IGRAs for the detection of tuberculosis
disease or LTBI in children remains to be determined. In high-
income countries where the detection of individuals with LTBI
remains the priority, many advocate a role for IGRAs in con-
ﬁrming a positive TST result. In contrast, the role of IGRAs, if
any, for the detection of tuberculosis disease or to support
a diagnosis in children in low-income countries remains
questionable [55]. In these settings, currently available IGRAs
Table 1. Comparison of Results From Studies Comparing the Sensitivity of Interferon–g Assays and Tuberculin Skin Test (TST) in
Children With Culture-Confirmed Tuberculosis Disease
Sensitivity, % (95% CI)
a
Study QFT-G/QFT-GIT ELISPOT/T.SPOT.TB TST
Low tuberculosis prevalence
Kampmann 2009 (n 5 25) 0.80 (.59–.93) 0.58 (.37–.78) 0.88 (.72–.96)
Detjen 2007 (n 5 28) 0.93 (.77–.99) 0.93 (.77–.99) 1.0 (.88–1.00)
Bamford 2009 (n 5 49) 0.78 (.64–.89) 0.67 (.46–.83) 0.82 (.68–.92)
Bakir 2008 (n 5 15) . 0.73 (.47–.89) .
Haustein 2009 (n 5 16) 0.75 (.47–.92) . 0.67 (.38–.87)
Hermann 2009 (n 5 15) 0.78 (.60–.90) . 0.84 (.67–.94)
Latorre 2009 (n 5 13) 0.75 (.46–.91) 0.92 (.7–1.00) .
Tsolia 2010 (n 5 12) 1.00 (.70–1.00) . 10 (.91)
Cruz 2010 (n 5 13) . 0.92 (.65–.99) 0.77 (.49–.92)
High tuberculosis prevalence
Nicol 2005 (n 5 12) . 0.83 (.54–.95) .
Hansted 2009 (n 5 23) . 1.00 (.87–1.00) 1.00 (.87–1.00)
Nicol 2009 (n 5 10) . 0.50 (.23–.76) 0.80 (.49–.94)
Liebeschuetz 2004 (n 5 57) . 0.83 (.76–.93) 0.35 (.21–.51)
Warier 2009 (n 5 15) . 0.53 (.30–.75) 1.00 (.82–1.00)
HIV-infected
Liebeschuetz 2004 (n 5 30) . 0.74 (.54–.88) 0.36 (.18–.58)
Davies 2009 (n 5 22) . 0.64 (.41–.83) 0.33 (.15–.58)
Stavri 2009 (n 5 36) . 0.47 (.30–.65) 0.40 (.27–.93)
Abbreviations: Includes studies in which $10 children had conﬁrmed tuberculosis. CI, conﬁdence interval; ELISPOT, enzyme-linked immunospot assay; HIV,
human immunodeﬁciency virus; QFT-G, QuantiFERON-TB Gold assay; QFT-GIT, QuantiFERON-TB Gold In-Tube assay; TST, tuberculin skin test.
a Not every individual in each study had all tests done; stated sensitivity (95% CI) calculated using number who had test as denominator.
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the tuberculosis burden. First, commercial IGRAs are unable to
distinguish LTBI from tuberculosis disease. Although the search
for novel biomarkers with the ability to distinguish between
LTBI and tuberculosis disease continues [56], the challenge of
incorporating new diagnostic tests into existing tuberculosis
programs remains problematic. Second, IGRAs remain opera-
tionally too complex and costly for use in such settings. Third,
IGRAs provide only indirect evidence of M. tuberculosis in-
fection and do not assist with identiﬁcation of drug resistance.
Additional research is required to identify improved, more
accurate, and simple immune-based blood tests for use in young
children in high tuberculosis burden settings. In high-income
countries, unraveling the underlying reasons behind discordant
results between the TST and IGRAs would represent a major
advance.
CONCLUSION
The identiﬁcation of improved diagnostic tests for tuberculosis
has been identiﬁed as a global research priority. Although test
developers typically focus on adult populations, it is likely that
many of the new generation of tests will have applicability for
childhood tuberculosis. There is a need to continue to advocate
for test development targeted at this vulnerable and neglected
population and to rapidly assess the performance of novel tu-
berculosis diagnostic tests in pediatric populations.
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